---

---

sector : Professional, scientific, and technical services    symbols : Lly   

save search

---

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 12:30) - globenewswire.com
VERV | $6.66 -1.19% -1.2% 1.2M |

Professional, Scientific, and T...

| -53.32% | O: 5.89% H: 15.96% C: 14.72%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -2.74% | O: -2.2% H: 2.39% C: 1.34%
VRTX | News | $393.51 0.1% 0.1% 950K |

Health Technology

| -8.89% | O: 0.15% H: 0.66% C: -0.74%
year pipeline therapeutics financial results

---

Protein Inhibitors Global Market Report 2024 - A $125 Billion Market in 2028, Registering Compound Annual Growth of 9%
Published: 2024-02-14 (Crawled : 02:00) - prnewswire.com
LZAGF | $579.0 -19.1% 49 |

Health Technology

| 12.7% | O: 3.14% H: 1.92% C: 1.92%
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -3.81% | O: -2.14% H: 0.0% C: -0.63%
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -0.29% | O: -2.71% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 9.56% | O: 0.87% H: 0.21% C: -2.23%
LZAGY | $57.3 0.02% 33K |

Professional, Scientific, and T...

| 15.41% | O: 4.07% H: 1.53% C: 1.45%
TMO | News | $541.52 -1.05% 0.61% 2.1M |

Health Technology

| -1.04% | O: 0.56% H: 1.3% C: 1.22%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -8.3% | O: 0.42% H: 1.04% C: 0.97%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -8.08% | O: -0.91% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -4.32% | O: 0.89% H: 0.41% C: 0.1%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 1.05% | O: 0.38% H: 2.44% C: 1.54%
BAX | $39.65 0.33% 0.0% 2.3M |

Health Technology

| 0.2% | O: 0.33% H: 0.63% C: -0.28%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| -5.33% | O: -0.73% H: 0.0% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M |

Health Technology

| -5.49% | O: -0.83% H: 0.66% C: 0.38%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -1.43% | O: -1.1% H: 0.0% C: 0.0%
GLPG | $28.9 -1.1% -1.11% 140K |

Health Technology

| -25.19% | O: -1.72% H: 1.8% C: 1.59%
BIIB | $190.55 -0.84% -0.84% 1.5M |

Health Technology

| -13.9% | O: 0.16% H: 0.43% C: -2.76%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 11.85% | O: 0.28% H: 0.93% C: 0.75%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -8.79% | O: -0.21% H: 0.34% C: 0.07%
report global protein growth market

---

Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
Published: 2023-12-01 (Crawled : 21:00) - globenewswire.com
VERV | $6.66 -1.19% -1.2% 1.2M |

Professional, Scientific, and T...

| Email alert Add to watchlist
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| Email alert Add to watchlist
offering therapeutics

---

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
Published: 2023-11-29 (Crawled : 04:00) - globenewswire.com
VERV | $6.66 -1.19% -1.2% 1.2M |

Professional, Scientific, and T...

| -43.5% | O: -11.15% H: 13.21% C: 5.66%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 26.85% | O: -0.06% H: 0.0% C: 0.0%
offering therapeutics

---

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
VERV | $6.66 -1.19% -1.2% 1.2M |

Professional, Scientific, and T...

| -43.5% | O: -11.15% H: 13.21% C: 5.66%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 26.85% | O: -0.06% H: 0.0% C: 0.0%
offering therapeutics

---

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
Published: 2023-11-07 (Crawled : 12:00) - globenewswire.com
VERV | $6.66 -1.19% -1.2% 1.2M |

Professional, Scientific, and T...

| -55.01% | O: 6.88% H: 25.67% C: 16.8%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 31.04% | O: 4.2% H: 0.83% C: 0.49%
company therapeutics financial results

---

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
Published: 2023-10-31 (Crawled : 10:00) - globenewswire.com
VERV | $6.66 -1.19% -1.2% 1.2M |

Professional, Scientific, and T...

| -28.37% | O: 5.31% H: 28.36% C: 21.49%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 32.07% | O: -0.03% H: 0.0% C: 0.0%

---

Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics
Published: 2023-10-13 (Crawled : 16:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K |

Health Technology

| -28.12% | O: -1.86% H: 0.0% C: 0.0%
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -30.76% | O: -2.78% H: 0.04% C: -0.57%
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 17.55% | O: -0.21% H: 0.42% C: -1.17%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -4.89% | O: -0.55% H: 0.69% C: -0.09%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -6.93% | O: 0.64% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 23.38% | O: 1.15% H: 0.0% C: 0.0%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| 11.37% | O: 0.38% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 0.23% | O: -0.59% H: 0.62% C: -0.56%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -7.05% | O: 0.93% H: 0.26% C: -1.25%
management growing

---

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Published: 2023-10-13 (Crawled : 13:00) - prnewswire.com
PYXS | $4.51 -6.63% -7.1% 470K |

Professional, Scientific, and T...

| 147.69% | O: 0.0% H: 2.56% C: 2.56%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 23.38% | O: 1.15% H: 0.0% C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K |

Health Technology

| -40.22% | O: -1.63% H: 4.97% C: 2.76%
MRUS | $40.41 -1.56% -1.58% 240K |

Health Technology

| 94.73% | O: 0.47% H: 1.7% C: -0.38%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 0.23% | O: -0.59% H: 0.62% C: -0.56%
fda year review cancer pancreatic

---

Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim
Published: 2023-08-03 (Crawled : 21:00) - prnewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M |

Professional, Scientific, and T...

| -37.04% | O: -0.11% H: 4.35% C: 1.85%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 66.3% | O: -0.53% H: 0.0% C: 0.0%
RCUS 4 | $14.84 0.0% 840K |

Health Technology

| -22.02% | O: 0.11% H: 1.42% C: -0.16%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -9.29% | O: 2.43% H: 0.0% C: 0.0%
MRUS | $40.41 -1.56% -1.58% 240K |

Health Technology

| 57.76% | O: -0.23% H: 1.85% C: 0.15%
INCY | $52.82 0.19% 0.19% 1.8M |

Health Technology

| -18.71% | O: -0.8% H: 0.99% C: -1.29%
GRTX | $0.185 -6.75% -7.24% 3.8M |

Health Technology

| -91.48% | O: 0.45% H: 4.02% C: 0.45%
BNTX | $86.19 -0.24% -0.24% 580K |

Health Technology

| -19.2% | O: -0.01% H: 1.23% C: -0.15%
AGEN | $4.97 -7.96% -8.65% 1.7M |

Health Technology

| 242.76% | O: 0.69% H: 3.08% C: 0.0%
companies expected pancreatic tumor endocrine growth market

---

Diabetic Peripheral Neuropathy Market Growing at a CAGR of ~6% by 2032 | DelveInsight
Published: 2023-07-20 (Crawled : 21:00) - prnewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M |

Professional, Scientific, and T...

| -43.76% | O: 0.71% H: 3.64% C: 0.61%
NVO | $122.75 -1.43% 0.0% 2.8M |

Health Technology

| -24.29% | O: -0.16% H: 1.18% C: 0.88%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 61.87% | O: 0.34% H: 0.35% C: -0.72%
VRTX | News | $393.51 0.1% 0.1% 950K |

Health Technology

| 9.16% | O: 0.86% H: 0.57% C: -0.68%
APLT A | $4.74 -1.86% -1.9% 720K |

Health Technology

| 275.91% | O: 1.46% H: 6.12% C: 2.88%
ALT | $6.9 -1.99% -2.03% 3.2M |

Commercial Services

| 116.67% | O: 1.57% H: 0.0% C: -2.79%
growing market diabetic

---

Metastatic Pancreatic Cancer Market to Proliferate Immensly, Predicts DelveInsight | Key Companies to Look Out for - FibroGen, AstraZeneca, Jiangsu HengRui, ImmunityBio, SynerGene, Mirati, Incyte, Astellas, AbbVie, Cue Biopharma, PureTech
Published: 2023-06-15 (Crawled : 15:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -42.8% | O: -0.92% H: 0.0% C: -0.37%
BMEA | $11.18 -2.78% -2.86% 1.7M |

Professional, Scientific, and T...

| -69.28% | O: -0.15% H: 0.0% C: -5.2%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 67.69% | O: 0.06% H: 1.91% C: 1.32%
INCY | $52.82 0.19% 0.19% 1.8M |

Health Technology

| -14.03% | O: -0.11% H: 2.08% C: 1.97%
companies cue cancer pancreatic market

---

Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
Published: 2023-06-15 (Crawled : 11:00) - globenewswire.com
VERV | $6.66 -1.19% -1.2% 1.2M |

Professional, Scientific, and T...

| -60.58% | O: 2.4% H: 14.05% C: 13.31%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 67.69% | O: 0.06% H: 1.91% C: 1.32%
disease treatment global collaboration program cardiovascular

---

Protein Assays Global Market Report 2023: Increasing Research in Proteomics Bolsters Sector
Published: 2023-03-27 (Crawled : 00:00) - prnewswire.com
LZAGF | $579.0 -19.1% 49 |

Health Technology

| -3.68% | O: 0.21% H: 0.57% C: -2.7%
LZAGY | $57.3 0.02% 33K |

Professional, Scientific, and T...

| -2.6% | O: -1.21% H: 0.0% C: -0.33%
TMO | News | $541.52 -1.05% 0.61% 2.1M |

Health Technology

| -5.11% | O: -0.3% H: 0.48% C: -1.03%
PKI | $115.24 0.0% 1.6M |

Health Technology

| -9.87% | O: -1.13% H: 0.84% C: 0.56%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 124.38% | O: 0.36% H: 0.9% C: 0.55%
NSTG | $0.1053 -37.43% -0.19% 0 |

Health Technology

| -98.83% | O: -1.0% H: 2.13% C: 0.11%
TECH | $62.25 -0.77% -0.77% 1.2M |

Health Technology

| -14.55% | O: -0.35% H: 0.39% C: -2.09%
ABCM | $23.99 0.0% 7.4M |

Health Technology

| 81.33% | O: 0.0% H: 0.68% C: -0.68%
report research global protein market

---

Regenerative Medicine Market to be Worth $180.87 Billion by 2030: Grand View Research, Inc.
Published: 2023-02-14 (Crawled : 10:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560 |

Health Technology

| -2.85% | O: 0.43% H: 1.52% C: -1.88%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 28.82% | O: 0.34% H: 0.0% C: 0.0%
USRM | $0.0001 1300.0% 290K |

Professional, Scientific, and T...

| -97.78% | O: 2.22% H: 4.35% C: 4.35%
PFE A | $25.39 -0.12% -0.12% 36M |

Health Technology

| -42.21% | O: 0.23% H: 0.25% C: -0.84%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| 6.39% | O: 0.27% H: 0.42% C: -0.21%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 114.26% | O: 0.04% H: 0.93% C: -0.85%
NUVA | $39.75 -2.24% -2.29% 0 |

Health Technology

| -10.15% | O: -0.16% H: 2.24% C: 0.79%
MDXG | $6.17 -2.53% -2.59% 540K |

Health Technology

| 37.01% | O: -1.3% H: 2.85% C: 2.19%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -2.07% | O: 0.3% H: 0.94% C: 0.6%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| 8.73% | O: -0.39% H: 0.12% C: -0.69%
market

---

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights
Published: 2022-08-15 (Crawled : 23:00) - biospace.com/
ABOS | $3.18 -8.36% -9.12% 640K |

Professional, Scientific, and T...

| -35.74% | O: 0.19% H: 1.85% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 143.69% | O: 0.37% H: 1.75% C: 1.53%

---

LAMEA Peptide Therapeutics Market Report 2022: Annual Growth of 12.5% Expected Through 2028
Published: 2022-08-05 (Crawled : 15:20) - prnewswire.com
LZAGF | $579.0 -19.1% 49 |

Health Technology

| -5.42% | O: -4.5% H: 0.0% C: 0.0%
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -2.01% | O: -6.04% H: 2.59% C: 2.59%
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -4.85% | O: 3.16% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 1.47% | O: 0.59% H: 0.0% C: -4.45%
LZAGY | $57.3 0.02% 33K |

Professional, Scientific, and T...

| -5.41% | O: -3.78% H: 0.57% C: 0.36%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -5.6% | O: -0.65% H: 0.29% C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M |

Health Technology

| -49.02% | O: -0.44% H: 0.66% C: -0.75%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| 9.21% | O: -0.16% H: 0.71% C: 0.56%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -2.46% | O: -1.26% H: 1.36% C: 1.2%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 145.52% | O: -1.08% H: 0.94% C: -0.38%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -7.82% | O: -0.32% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 2.98% | O: -0.63% H: 0.63% C: 0.24%
report expected therapeutics growth market

---

Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
Published: 2022-06-28 (Crawled : 12:20) - globenewswire.com
AKYA | $3.855 -1.41% -1.43% 260K |

Professional, Scientific, and T...

| -66.94% | O: 1.0% H: 4.77% C: 3.37%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 132.0% | O: 0.99% H: 0.0% C: 0.0%
oncosignature test diagnostic therapeutics

---

BioSpace Movers & Shakers: ADC, Akari, Scorpion & More
Published: 2022-06-17 (Crawled : 13:00) - biospace.com/
CMRA | $0.041 70.59% 2K |

n/a

| -98.3% | O: -5.71% H: 49.39% C: 34.55%
FNCTF | News | $11.0354 -20.84% 34K |

Communications

| -4.95% | O: -4.49% H: 0.0% C: 0.0%
LZAGF | $579.0 -19.1% 49 |

Health Technology

| 12.93% | O: 0.24% H: 0.0% C: 0.0%
LZAGY | $57.3 0.02% 33K |

Professional, Scientific, and T...

| 14.05% | O: 0.58% H: 1.5% C: 0.83%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -13.87% | O: 1.35% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 159.72% | O: 0.33% H: 0.0% C: 0.0%
BSX | $67.42 -0.8% -0.53% 5.9M |

Health Technology

| 92.63% | O: 1.69% H: 2.14% C: 1.18%

---

Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
Published: 2021-12-02 (Crawled : 13:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K |

Professional, Scientific, and T...

| -70.71% | O: -12.78% H: 1.91% C: -0.87%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 200.81% | O: -1.21% H: 0.0% C: 0.0%
rosa therapeutics

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---